Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for stubborn scalp psoriasis

NCT ID NCT05478499

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The main goal was to see if more people achieved clear or almost clear scalp skin after 16 weeks of treatment. This is a disease-control study, meaning the treatment aims to manage symptoms rather than cure the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

154 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator 2. Deemed by the Investigator to be a candidate for phototherapy or systemic therapy 3. Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1 4. ≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1 5. Evidence of plaque psoriasis in a non-scalp area 6. Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis Exclusion Criteria: * Target Disease Exceptions: 1. Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • Local Institution - 0001

    Hot Springs, Arkansas, 71913, United States

  • Local Institution - 0002

    New Brighton, Minnesota, 55432, United States

  • Local Institution - 0003

    Portland, Oregon, 97201, United States

  • Local Institution - 0004

    San Antonio, Texas, 78229, United States

  • Local Institution - 0005

    Pittsburgh, Pennsylvania, 15213, United States

  • Local Institution - 0006

    Norfolk, Virginia, 23502, United States

  • Local Institution - 0007

    Indianapolis, Indiana, 46256, United States

  • Local Institution - 0008

    Beverly, Massachusetts, 01915, United States

  • Local Institution - 0011

    Mahlow, 15831, Germany

  • Local Institution - 0012

    Lübeck, 23538, Germany

  • Local Institution - 0013

    Frankfurt am Main, Hesse, 60590, Germany

  • Local Institution - 0014

    Rzeszów, 35-055, Poland

  • Local Institution - 0015

    Wroclaw, 51-685, Poland

  • Local Institution - 0017

    Lodz, 90-436, Poland

  • Local Institution - 0019

    Paris, 75010, France

  • Local Institution - 0022

    Rockville, Maryland, 20850, United States

  • Local Institution - 0026

    Krakow, 30438, Poland

  • Local Institution - 0031

    London, Greater London, SE1 9RT, United Kingdom

  • Local Institution - 0033

    Houston, Texas, 77004, United States

  • Local Institution - 0038

    Witten, Deutschland, 58454, Germany

  • Local Institution - 0039

    Southampton, HAMPSHIRE, SO16 6DU, United Kingdom

  • Local Institution - 0040

    Romans-sur-Isère, 26102, France

  • Local Institution - 0041

    Louisville, Kentucky, 40217, United States

  • Local Institution - 0044

    Rouen, 76031, France

  • Local Institution - 0045

    Salford, Greater Manchester, M6 8HD, United Kingdom

  • Local Institution - 0047

    Bloomfield Hills, Michigan, 48302, United States

  • Local Institution - 0048

    Hamburg, 20246, Germany

  • Local Institution - 0049

    East Windsor, New Jersey, 08520, United States

  • Local Institution - 0051

    Kew Gardens, New York, 11415, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.